查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
仿製药市场-全球行业规模、份额、趋势、机会和预测，2018-2028 年，按类型、按应用、按药物输送、按形式、按来源、按分销渠道、按地区、按竞争对手
市场调查报告书
商品编码
1266841

仿製药市场-全球行业规模、份额、趋势、机会和预测，2018-2028 年，按类型、按应用、按药物输送、按形式、按来源、按分销渠道、按地区、按竞争对手

Generic Drugs Market- Global Industry Size, Share, Trends, Opportunity and Forecast, 2018-2028F By Type, By Application, By Drug Delivery, By Form, By Source, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 312 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

仿製药市场预计到 2022 年价值 4160.6 亿美元，并在预测期内以 6.51% 的复合年增长率进一步增长，这是由于对仿製药的需求不断增长。

仿製药市场在未来几年将继续增长，原因包括慢性病患者增多、专利到期、对低价药物的需求增加、仿製药易于获得以及政府支持仿製药上市预计将继续增长。

慢性病患病率增加

由于遗传、环境、行为和生理因素等长期疾病，慢性病患病率上升将推动预测期内的市场增长。 慢性病影响全世界所有年龄组。 此外，慢性阻塞性肺病和哮喘等慢性呼吸系统疾病以及恶性肿瘤、糖尿病和心血管疾病等非传染性疾病是最常见的疾病，这将在预测期内进一步增加对仿製药的需求。 同样，快速城市化、不健康生活方式的全球化和人口老龄化等主要因素预计将在预测期内推动市场增长。 糖尿病、癌症和心血管疾病等慢性病的全球患病率正在迅速增加。 因此，对负担得起的有效治疗的需求不断增长，推动了仿製药市场的增长。 换句话说，患者更喜欢仿製药，因为需求会随着时间的推移而增加。 根据全国健康访谈调查，美国 51.8% 的成年人患有一种慢性病，约 27% 的人患有多种慢性病。 据世界卫生组织称，全世界每年有 3800 万人受到慢性病的影响。 据世界卫生组织称，慢性病导致约 4100 万人死亡，占全球所有死亡人数的 71%。 其中，1790 万人死于心脏病，930 万人死于癌症，410 万人死于呼吸系统疾病，150 万人死于糖尿病。 此外，吸烟、饮酒增加和缺乏锻炼等其他因素也影响了市场增长。

慢性病会对仿製药市场的增长产生重大影响。 慢性病是一种长期存在的疾病，需要持续的医疗护理，而且通常需要使用药物。 慢性病的例子包括糖尿病、高血压、关节炎和心脏病。 仿製药通常比品牌产品便宜，这使它们成为许多慢性病患者的有吸引力的选择。 这是因为仿製药製造商不必投入昂贵的研发和市场开发，以较低的价格形式转嫁给消费者。 世界卫生组织报告称，慢性病是全球死亡的主要原因，占 2019 年所有死亡人数的 71%。 然而，根据世界卫生组织 (WHO) 的《2021 年全球吸烟流行趋势报告》，全球吸烟流行率将从 2000 年的 27% 下降到 2020 年的 20%。我来了。

对仿製药的需求不断增长

品牌药的专利到期是全球仿製药市场的增长动力，为创新创造了机会，并使患者更容易获得药物。 当品牌药的专利到期时，它会对全球仿製药市场产生重大影响。 一旦专利到期，其他製造商可以生产和销售该药物的仿製药，通常价格低于品牌药。 这为仿製药製造商进入市场并为消费者提供更实惠的选择创造了机会。 因此，对仿製药的需求将增加，从而推动仿製药市场的增长。 例如，西妥昔单抗是一种表皮生长因子受体抑製剂，用于治疗转移性结直肠癌和头颈癌。 在欧洲，它由 Bristol-Myers Squibb 和 Eli Lilly 根据 2018 年到期的专利生产。 因此，许多市场参与者有望提供製造后续产品的机会。

除了竞争加剧和价格下降之外，专利到期还可能导致仿製药市场的创新。 仿製药製造商可能会开发新的药物配方和给药方法，以提高药物的疗效和患者的便利性。

但是，请务必记住，并非所有药物在专利到期后都会对仿製药市场产生重大影响。 根据药物的不同，仿製药製造商生产它可能无利可图，或者品牌药可能具有仿製药无法轻易复製的独特特性。 此外，FDA 对加速生物仿製药开发的支持正在鼓励製造商专注于他们的开发。 一旦品牌药的专利到期，仿製药製造商就可以进入市场并生产价格较低的药物。 然而，专利纠纷和原药製造商延迟竞争的策略可能会延迟仿製药的可用性。

对低成本药物的需求增加

低价仿製药将对全球仿製药市场产生重大影响，使患者更能负担得起药品，减轻医疗保健系统的财务负担，并刺激製药行业的创新。要做。 仿製药通常比品牌药便宜，这使它们成为患者更负担得起的选择。 获得廉价药品的机会有限，特别是在发展中国家，因此低价仿製药的可用性会对医疗保健系统产生重大影响。 因此，这些地区对仿製药的需求增加，这有助于全球仿製药市场的增长。 仿製药节省的成本也有利于医疗保健提供者、保险公司和政府。 医疗保健提供者可以通过使用仿製药降低患者的治疗成本，改善获得护理的机会，并减轻患者及其家人的经济负担。

此外，为了降低成本，低价仿製药还可以鼓励製药行业的创新。 随着公司竞相生产最便宜和最有效的仿製药，他们可能会在研发方面投入更多资金，以改进药物配方、给药和疗效。 2021 年 12 月，美国 FDA 批准了 Gilenya 的第一个仿製药，这是一种用于治疗多发性硬化症的药物。

近期发展

  • 2021 年 11 月，印度政府宣布了一项新政策，旨在降低成本并促进仿製药在该国的使用。
  • 2021 年 9 月，发表在《美国医学会杂誌》上的一项研究发现，在美国使用仿製药可为糖尿病患者节省大量费用。
  • 2021 年 8 月，美国 FDA 批准了 Advair Discus 的第一个仿製药，这是一种用于治疗哮喘和慢性阻塞性肺疾病 (COPD) 的药物。
  • 2021 年 7 月，世界卫生组织 (WHO) 发起了一项新举措，旨在扩大仿製药的普及范围并降低全球的药品成本。

可自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

  • 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析

内容

第 1 章概述

  • 市场定义
  • 市场范围
    • 目标市场
    • 研究目标年份
    • 主要市场细分

第二章研究方法论

  • 调查目的
  • 基线调查方法
  • 主要行业合作伙伴
  • 主要协会和次要信息
  • 调查方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章执行摘要

  • 市场概览
  • 主要市场细分概述
  • 主要市场参与者概览
  • 主要地区/国家概览
  • 市场驱动因素、挑战和趋势

第 4 章 VOC（客户之声）

第 5 章仿製药的全球市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按类型（低分子仿製药和生物仿製药）
    • 按应用（心血管疾病、糖尿病、神经病学、癌症、抗炎性疾病等）
    • 通过给药（口服、局部、肠胃外、其他）
    • 按剂型（片剂、胶囊剂、注射剂等）
    • 按供应商分类（内部製造组织与合同製造组织之间的区别）
    • 按分销渠道（医院药店、零售药店、在线药店、其他）
    • 按公司分类（2022 年）
    • 按地区
  • 市场地图
    • 按类型
    • 通过申请
    • 通过给药
    • 按表格
    • 按来源
    • 按分销渠道
    • 按地区

第六章北美仿製药市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按类型
    • 通过申请
    • 通过给药
    • 按表格
    • 按来源
    • 按分销渠道
    • 按国家
  • 北美：国家/地区分析
    • 美国
    • 墨西哥
    • 加拿大

第七章欧洲仿製药市场前景

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按类型
    • 通过申请
    • 通过给药
    • 按表格
    • 按来源
    • 按分销渠道
    • 按国家
  • 欧洲：国家分析
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙

第八章亚太仿製药市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按类型
    • 通过申请
    • 通过给药
    • 按表格
    • 按来源
    • 按分销渠道
    • 按国家
  • 亚太地区：国家/地区分析
    • 中国
    • 日本
    • 韩国
    • 印度
    • 澳大利亚

第9章南美仿製药市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按类型
    • 通过申请
    • 通过给药
    • 按表格
    • 按来源
    • 按分销渠道
    • 按国家
  • 南美洲：：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第 10 章中东和非洲仿製药市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按类型
    • 通过申请
    • 通过给药
    • 按表格
    • 按来源
    • 按分销渠道
    • 按国家
  • MEA：国家分析
    • 南非仿製药
    • 沙特阿拉伯仿製药
    • 阿联酋仿製药
    • 科威特仿製药

第 11 章市场动态

  • 主持人
  • 做

第12章市场趋势与发展

  • 近期发展状况
  • 併购
  • 产品发布

第 13 章仿製药全球市场：SWOT 分析

第 14 章波特的五力分析

  • 行业竞争
  • 新进入的可能性
  • 供应商的力量
  • 客户力量
  • 替代品的威胁

第15章竞争格局

  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH（Novartis AG）
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • STADA Arzneimittel AG
  • Aurobindo Pharma Limited
  • Dr Reddy's Laboratories Ltd
  • Cipla Ltd
  • Novo Nordisk A/S
  • Abbott Laboratories Inc.
  • Endo Pharmaceuticals Inc.
  • Sanofi SA
  • Aspen Pharmacare Holdings Limited
  • Lupin Limited

第16章 战略建议

Product Code: 7332

Generic Drugs Market was valued at USD 416.06 billion in 2022 and is further anticipated to grow at a CAGR of 6.51%, during the forecast period, owing to rising demand for generic drugs. The Generic Drugs market is expected to continue growing in the coming years, driven by factors such as the increasing prevalence of chronic diseases, expiration of patent drugs, growing demand for low-cost drugs, and easy accessibility and supportive governments for allowing generic drugs in the market.

The increasing aging population, along with the growing demand for low-cost generic drugs, will further drive the growth of the market during the forecast period. As consumers become more aware of the cost savings and efficacy of generic drugs, they are more likely to choose them over branded drugs which is a factor expected to drive the growth of the market during the forecast period. Generic drugs are used to treat a wide range of medical conditions, just like their branded counterparts. They contain the same active ingredients and are equivalent in strength, dosage, safety, and effectiveness.

Advancements in generic drugs have also contributed to the growth of the Generic Drugs market. Some generic drugs are now being developed as combination therapies, which combine two or more drugs into a single pill or other delivery systems. This can increase patient compliance and reduce the overall cost of treatment.

While the Generic Drugs market is growing rapidly, there are also several challenges that are impeding its growth. One of the biggest challenges the global generic drugs market is facing is ensuring the quality of generic drugs is the same as branded drugs. Others are Regulatory hurdles for approval of the generic drugs along with pricing pressures. Patent litigation is also a challenge that will hamper the growth of the global generic drugs market.

Growing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases due to long-term illnesses such as genetic, environmental, behavioral, and physiological factors will drive the growth of the market during the forecast period. Chronic diseases impact all ages across the globe. Also, non-communicable diseases such as chronic respiratory diseases such as COPD, asthma, malignancies and, diabetes, cardiovascular diseases are the most common diseases, which will further increase the demand for generic drugs in the forecast period. Similarly, some major factors like rapid urbanization, globalization of leading unhealthy lifestyle, and the growing aging population is expected to drive the growth of the market during the forecast period. The global prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases is increasing rapidly. As a result, there is a growing demand for affordable and effective treatments, which has driven the growth of the generic drugs market. So, patients prefer generic drugs as demand grows with time. According to the National Health Interview Survey, 51.8% of U.S adults have one chronic disease, and approx. 27% of people are suffering from several chronic diseases. Per year, 38 million people are affected because of chronic diseases across the globe, according to WHO. According to WHO, chronic diseases affect almost 41 million people, which is equivalent to 71% of all deaths globally; among these, 17.9 million deaths are caused for heart disease, 9.3 million deaths are caused due to cancer, and 4.1 million deaths due to respiratory diseases, 1.5 million deaths due to diabetes per year. Additionally, other factors are also influencing the growth of the market, such as exposure to the use of tobacco, increasing consumption of alcohol, and physical inactivity.

Chronic diseases can have a significant impact on the growth of the generic drugs market. Chronic diseases are long-lasting medical conditions that require ongoing medical attention and often require the use of medication. Examples of chronic diseases include diabetes, hypertension, arthritis, and heart disease. Generic drugs are an attractive option for many patients with chronic diseases because they are typically less expensive than their branded counterparts. This is because generic drug manufacturers do not have to invest in expensive research and development or marketing campaigns, which can be passed on to consumers in the form of lower prices. The WHO also reports that chronic diseases are the leading cause of death worldwide, accounting for 71% of all deaths in 2019. However, according to the World Health Organization's 2021 Global Report on Trends in Prevalence of Tobacco Smoking, the global prevalence of smoking has decreased from 27% in 2000 to 20% in 2020.

Growing Demand for Generic Drugs

The expiration of patents for branded drugs is a major driver of growth in the global generic drugs market, creating opportunities for innovation and making medications more accessible to patients. The expiration of patents for branded drugs can have a significant impact on the global generic drugs market. When a patent expires, it allows other manufacturers to produce and sell generic versions of the drug, often at a lower cost than the branded drug. This creates an opportunity for generic drug manufacturers to enter the market and offer more affordable options to consumers. As a result, the demand for generic drugs increases, driving growth in the generic drugs market. For example, Cetuximab is an epidermal growth factor receptor inhibitor that is used for the treatment of metastatic colorectal cancer and head and neck cancer. It is manufactured under the patent by Bristol-Myers Squibb and Eli Lily Company in Europe, and it expired in 2018. It is thus expected to provide an opportunity for a large number of market players to manufacture its generic version.

In addition to increasing competition and lowering prices, the expiration of patents can also lead to innovation in the generic drugs market. Generic drug manufacturers may develop new formulations or delivery methods for the drug, improving its efficacy and convenience for patients.

However, it is important to note that not all drugs have a significant impact on the generic drugs market when their patents expire. Some drugs may not be profitable for generic manufacturers to produce, or the original drug may have unique properties that cannot be easily replicated by a generic version. Additionally, a supportive initiative by the FDA for promoting the development of biosimilars is encouraging manufacturers to focus on its development. As patents on brand-name drugs expire, generic drug manufacturers can enter the market and produce lower-cost versions of the drug. However, the availability of generic drugs can still be delayed if there are patent disputes or if the brand-name manufacturer implements strategies to delay competition.

Growing Demand for Low-Cost Drugs

Low-cost generic drugs have a significant impact on the global generic drugs market, making medications more affordable and accessible to patients, reducing the financial burden on healthcare systems, and driving innovation in the pharmaceutical industry. Generic drugs are typically less expensive than their branded counterparts, which makes them a more affordable option for patients. The availability of low-cost generic drugs can have a major impact on healthcare systems, particularly in developing countries, where access to affordable medications can be limited. This has led to increased demand for generic drugs in these regions, which has, in turn, contributed to the growth of the global generic drugs market. The cost savings associated with generic drugs also benefit healthcare providers, insurance companies, and governments. By using generic drugs, healthcare providers can reduce the cost of treatment for their patients, which can improve access to care and reduce the financial burden on patients and their families.

Additionally, to lower costs, low-cost generic drugs can also drive innovation in the pharmaceutical industry. As companies compete to produce the most affordable and effective generic versions of a drug, they may further invest in research and development to improve the formulation, delivery, and efficacy of the drug. In December 2021, the US FDA approved the first generic version of the drug Gilenya, used to treat multiple sclerosis.

Recent Development

  • In November 2021, the Indian government announced a new policy aimed at reducing the cost of generic drugs and promoting their use in the country.
  • In September 2021, a study published in the Journal of the American Medical Association found that the use of generic drugs can lead to significant cost savings for patients with diabetes in the United States.
  • In August 2021, the US FDA approved the first generic version of the drug Advair Diskus, used to treat asthma and chronic obstructive pulmonary disease (COPD).
  • In July 2021, the World Health Organization (WHO) launched a new initiative aimed at increasing access to generic drugs and reducing the cost of medications worldwide.

Market Segmentation

Global generic drugs market is segmented based on type, application, drug delivery, form, source, distribution channel, and region. Based on type, the market is divided into Small Molecule Generics vs. Biosimilars. Based on application, the market is further segmented into Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, and Others. Based on drug delivery, the market is differentiated into Oral, Topical, Parenteral, and Others. Based on form, the market is segmented into tablets, Capsules, Injections, and Others. Based on the source, the market is divided into In House vs. Contract Manufacturing Organizations. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others.

Market Players

Teva Pharmaceutical Industries Ltd, Sandoz International GmbH (Novartis AG), Viatris Inc., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, STADA Arzneimittel AG, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd, Cipla Ltd, Novo Nordisk A/S, Abbott Laboratories Inc., Endo Pharmaceuticals Inc., Sanofi SA, Aspen Pharmacare Holdings Limited, Lupin Limited, among others, are some of the key players operating in the global Generic Drugs Market.

Report Scope:

In this report, Global Generic Drugs Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Generic Drugs Market, By Type:

  • Small Molecule Generics
  • Biosimilars

Generic Drugs Market, By Application:

  • Cardiovascular Diseases
  • Diabetes
  • Neurology
  • Oncology
  • Anti-Inflammatory Diseases
  • Others

Generic Drugs Market, By Drug Delivery:

  • Oral
  • Topical
  • Parenteral
  • Others

Generic Drugs Market, By Form:

  • Tablet
  • Capsule
  • Injection
  • Others

Generic Drugs Market, By Source:

  • In House
  • Contract Manufacturing Organizations

Generic Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Generic Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Colombia
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global Generic Drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Generic Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Small Molecule Generics vs Biosimilars)
    • 5.2.2. By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others)
    • 5.2.3. By Drug Delivery (Oral, Topical, Parenteral, Others)
    • 5.2.4. By Form (Tablet, Capsule, Injection, Others)
    • 5.2.5. By Source (In House vs Contract Manufacturing Organizations)
    • 5.2.6. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
    • 5.2.7. By Company (2022)
    • 5.2.8. By Region
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Application
    • 5.3.3. By Drug Delivery
    • 5.3.4. By Form
    • 5.3.5. By Source
    • 5.3.6. By Distribution Channel
    • 5.3.7. By Region

6. North America Generic Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Drug Delivery
    • 6.2.4. By Form
    • 6.2.5. By Source
    • 6.2.6. By Distribution Channel
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Generic Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Drug Delivery
        • 6.3.1.2.4. By Form
        • 6.3.1.2.5. By Source
        • 6.3.1.2.6. By Distribution Channel
    • 6.3.2. Mexico Generic Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Drug Delivery
        • 6.3.2.2.4. By Form
        • 6.3.2.2.5. By Source
        • 6.3.2.2.6. By Distribution Channel
    • 6.3.3. Canada Generic Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Drug Delivery
        • 6.3.3.2.4. By Form
        • 6.3.3.2.5. By Source
        • 6.3.3.2.6. By Distribution Channel

7. Europe Generic Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Drug Delivery
    • 7.2.4. By Form
    • 7.2.5. By Source
    • 7.2.6. By Distribution Channel
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Generic Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Drug Delivery
        • 7.3.1.2.4. By Form
        • 7.3.1.2.5. By Source
        • 7.3.1.2.6. By Distribution Channel
    • 7.3.2. United Kingdom Generic Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Drug Delivery
        • 7.3.2.2.4. By Form
        • 7.3.2.2.5. By Source
        • 7.3.2.2.6. By Distribution Channel
    • 7.3.3. France Generic Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Drug Delivery
        • 7.3.3.2.4. By Form
        • 7.3.3.2.5. By Source
        • 7.3.3.2.6. By Distribution Channel
    • 7.3.4. Italy Generic Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Drug Delivery
        • 7.3.4.2.4. By Form
        • 7.3.4.2.5. By Source
        • 7.3.4.2.6. By Distribution Channel
    • 7.3.5. Spain Generic Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Drug Delivery
        • 7.3.5.2.4. By Form
        • 7.3.5.2.5. By Source
        • 7.3.5.2.6. By Distribution Channel

8. Asia-Pacific Generic Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Drug Delivery
    • 8.2.4. By Form
    • 8.2.5. By Source
    • 8.2.6. By Distribution Channel
    • 8.2.7. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Generic Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Drug Delivery
        • 8.3.1.2.4. By Form
        • 8.3.1.2.5. By Source
        • 8.3.1.2.6. By Distribution Channel
    • 8.3.2. Japan Generic Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Drug Delivery
        • 8.3.2.2.4. By Form
        • 8.3.2.2.5. By Source
        • 8.3.2.2.6. By Distribution Channel
    • 8.3.3. South Korea Generic Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Drug Delivery
        • 8.3.3.2.4. By Form
        • 8.3.3.2.5. By Source
        • 8.3.3.2.6. By Distribution Channel
    • 8.3.4. India Generic Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Drug Delivery
        • 8.3.4.2.4. By Form
        • 8.3.4.2.5. By Source
        • 8.3.4.2.6. By Distribution Channel
    • 8.3.5. Australia Generic Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Drug Delivery
        • 8.3.5.2.4. By Form
        • 8.3.5.2.5. By Source
        • 8.3.5.2.6. By Distribution Channel

9. South America Generic Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Drug Delivery
    • 9.2.4. By Form
    • 9.2.5. By Source
    • 9.2.6. By Distribution Channel
    • 9.2.7. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Generic Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Drug Delivery
        • 9.3.1.2.4. By Form
        • 9.3.1.2.5. By Source
        • 9.3.1.2.6. By Distribution Channel
    • 9.3.2. Colombia Generic Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Drug Delivery
        • 9.3.2.2.4. By Form
        • 9.3.2.2.5. By Source
        • 9.3.2.2.6. By Distribution Channel
    • 9.3.3. Argentina Generic Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Drug Delivery
        • 9.3.3.2.4. By Form
        • 9.3.3.2.5. By Source
        • 9.3.3.2.6. By Distribution Channel

10. Middle East and Africa Generic Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Drug Delivery
    • 10.2.4. By Form
    • 10.2.5. By Source
    • 10.2.6. By Distribution Channel
    • 10.2.7. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Generic Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Drug Delivery
        • 10.3.1.2.4. By Form
        • 10.3.1.2.5. By Source
        • 10.3.1.2.6. By Distribution Channel
    • 10.3.2. Saudi Arabia Generic Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Drug Delivery
        • 10.3.2.2.4. By Form
        • 10.3.2.2.5. By Source
        • 10.3.2.2.6. By Distribution Channel
    • 10.3.3. UAE Generic Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Drug Delivery
        • 10.3.3.2.4. By Form
        • 10.3.3.2.5. By Source
        • 10.3.3.2.6. By Distribution Channel
    • 10.3.4. Kuwait Generic Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Application
        • 10.3.4.2.3. By Drug Delivery
        • 10.3.4.2.4. By Form
        • 10.3.4.2.5. By Source
        • 10.3.4.2.6. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Generic Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (As Reported)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1. Teva Pharmaceutical Industries Ltd.
    • 15.6.2. Sandoz International GmbH (Novartis AG)
    • 15.6.3. Viatris Inc.
    • 15.6.4. Sun Pharmaceutical Industries Ltd.
    • 15.6.5. Fresenius Kabi AG
    • 15.6.6. STADA Arzneimittel AG
    • 15.6.7. Aurobindo Pharma Limited
    • 15.6.8. Dr Reddy's Laboratories Ltd
    • 15.6.9. Cipla Ltd
    • 15.6.10. Novo Nordisk A/S
    • 15.6.11. Abbott Laboratories Inc.
    • 15.6.12. Endo Pharmaceuticals Inc.
    • 15.6.13. Sanofi SA
    • 15.6.14. Aspen Pharmacare Holdings Limited
    • 15.6.15. Lupin Limited

16. Strategic Recommendations

List of Figures

  • Figure 1: Global Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 2: Global Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 3: Global Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 4: Global Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 5: Global Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 6: Global Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 7: Global Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 8: Global Generic Drugs Market Share, By Region, By Value, 2018-2028F
  • Figure 9: Global Generic Drugs Market Share, By Company, By Value, 2022
  • Figure 10: Global Generic Drugs Market Map, By Type, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 11: Global Generic Drugs Market Map, By Application, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 12: Global Generic Drugs Market Map, By Drug Delivery , Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 13: Global Generic Drugs Market Map, By Form, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 14: Global Generic Drugs Market Map, By Source, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 15: Global Generic Drugs Market Map, By Distribution Channel, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 16: Global Generic Drugs Market Map, By Region, Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 17: North America Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 18: North America Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 19: North America Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 20: North America Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 21: North America Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 22: North America Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 23: North America Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 24: North America Generic Drugs Market Share, By Country, By Value, 2018-2028F
  • Figure 25: United States Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 26: United States Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 27: United States Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 28: United States Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 29: United States Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 30: United States Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 31: United States Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 32: Canada Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 33: Canada Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 34: Canada Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 35: Canada Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 36: Canada Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 37: Canada Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 38: Canada Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 39: Mexico Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 40: Mexico Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 41: Mexico Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 42: Mexico Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 43: Mexico Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 44: Mexico Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 45: Mexico Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 46: Europe Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 47: Europe Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 48: Europe Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 49: Europe Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 50: Europe Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 51: Europe Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 52: Europe Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 53: Europe Generic Drugs Market Share, By Country, By Value, 2018-2028F
  • Figure 54: Germany Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 55: Germany Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 56: Germany Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 57: Germany Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 58: Germany Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 59: Germany Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 60: Germany Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 61: France Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 62: France Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 63: France Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 64: France Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 65: France Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 66: France Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 67: France Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 68: United Kingdom Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 69: United Kingdom Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 70: United Kingdom Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 71: United Kingdom Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 72: United Kingdom Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 73: United Kingdom Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 74: United Kingdom Generic Drugs Market Share, By Distribution Channel , By Value, 2018-2028F
  • Figure 75: Spain Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 76: Spain Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 77: Spain Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 78: Spain Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 79: Spain Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 80: Spain Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 81: Spain Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 82: Italy Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 83: Italy Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 84: Italy Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 85: Italy Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 86: Italy Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 87: Italy Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 88: Italy Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 89: Asia Pacific Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 90: Asia Pacific Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 91: Asia Pacific Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 92: Asia Pacific Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 93: Asia Pacific Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 94: Asia Pacific Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 95: Asia Pacific Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 96: Asia Pacific Generic Drugs Market Share, By Country, By Value, 2018-2028F
  • Figure 97: China Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 98: China Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 99: China Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 100: China Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 101: China Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 102: China Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 103: China Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 104: India Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 105: India Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 106: India Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 107: India Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 108: India Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 109: India Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 110: India Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 111: Japan Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 112: Japan Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 113: Japan Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 114: Japan Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 115: Japan Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 116: Japan Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 117: Japan Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 118: Australia Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 119: Australia Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 120: Australia Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 121: Australia Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 122: Australia Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 123: Australia Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 124: Australia Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 125: South Korea Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 126: South Korea Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 127: South Korea Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 128: South Korea Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 129: South Korea Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 130: South Korea Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 131: South Korea Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 132: South America Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 133: South America Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 134: South America Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 135: South America Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 136: South America Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 137: South America Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 138: South America Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 139: South America Generic Drugs Market Share, By Country, By Value, 2018-2028F
  • Figure 140: Brazil Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 141: Brazil Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 142: Brazil Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 143: Brazil Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 144: Brazil Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 145: Brazil Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 146: Brazil Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 147: Argentina Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 148: Argentina Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 149: Argentina Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 150: Argentina Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 151: Argentina Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 152: Argentina Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 153: Argentina Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 154: Colombia Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 155: Colombia Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 156: Colombia Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 157: Colombia Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 158: Colombia Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 159: Colombia Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 160: Colombia Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 161: Middle East & Africa Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 162: Middle East & Africa Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 163: Middle East & Africa Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 164: Middle East & Africa Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 165: Middle East & Africa Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 166: Middle East & Africa Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 167: Middle East & Africa Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 168: Middle East & Africa Generic Drugs Market Share, By Country, By Value, 2018-2028F
  • Figure 169: South Africa Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 170: South Africa Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 171: South Africa Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 172: South Africa Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 173: South Africa Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 174: South Africa Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 175: South Africa Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 176: Saudi Arabia Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 177: Saudi Arabia Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 178: Saudi Arabia Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 179: Saudi Arabia Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 180: Saudi Arabia Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 181: Saudi Arabia Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 182: Saudi Arabia Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F
  • Figure 183: UAE Generic Drugs Market Size, By Value (USD Billion), 2018-2028F
  • Figure 184: UAE Generic Drugs Market Share, By Type, By Value, 2018-2028F
  • Figure 185: UAE Generic Drugs Market Share, By Application, By Value, 2018-2028F
  • Figure 186: UAE Generic Drugs Market Share, By Drug Delivery, By Value, 2018-2028F
  • Figure 187: UAE Generic Drugs Market Share, By Form, By Value, 2018-2028F
  • Figure 188: UAE Generic Drugs Market Share, By Source, By Value, 2018-2028F
  • Figure 189: UAE Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028F